BIOBOHEMIA
This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use.
I accept
Close

Biobohemia's Pipeline

Biobohemia's strategy is based on development and rapid clinical entry of SANTAVAC cancer vaccines based on antiangiogenic essences, demonstration of clinical safety and efficacy of this approach, and follow-on development of additional immunotherapeutic candidates. This strategy will allow for the leveraging of initial development efforts of the most advanced candidate to allow expedient transition for the other candidates. Biobohemia's therapeutic pipeline includes technologically distinct candidate products:

  • Therapeutic SANTAVAC15 DC is an antiangiogenic SANTAVAC15-loaded allogeneic dendritic cell vaccine for autologous cell therapy, for production of which primary culture of allogeneic HMECs can be purchased to produce SANTAVAC; DCs should be obtained from patient's blood.
  • Preventive SANTAVAC25 DC is an antiangiogenic SANTAVAC25-loaded allogeneic dendritic cell vaccine for autologous cell therapy, for production of which commercially available allogeneic HMECs can be purchased to produce SANTAVAC; DCs should be obtained from patient's blood.
  • Therapeutic SANTAVAC15 vaccine is a peptide vaccine composed of allogeneic SANTAVAC15 mixed with adjuvant.
  • Preventive SANTAVAC25 vaccine is a peptide vaccine composed of allogeneic SANTAVAC25 mixed with adjuvant.

In addition to encompassing technologically distinct candidates, the therapeutic pipeline encompasses separate formulations that can also target different types of cancer. Notwithstanding, the development programs are all highly focused on one target: antigen compositions developed by antigenic essence technology and intended for the development of cancer vaccines against solid tumors. This circumstance simplifies the overall R&D efforts and creates synergy among all of the programs, allowing the programs and their associated achievements to leverage each other. The development programs may be corrected according to the results of animal testing.
Drug
IND
Therapeutic
SANTAVAC15 DC

dendritic cell vaccine
Preventive
SANTAVAC25 DC

dendritic cell vaccine
Therapeutic
SANTAVAC
15

vaccine
Preventive
SANTAVAC
25

vaccine
Pre-Clinical
Phase 3
Phase 2
Phase 1